🚀 VC round data is live in beta, check it out!
INIFY Laboratories Valuation Multiples
Discover revenue and EBITDA valuation multiples for INIFY Laboratories and similar public comparables like Novacyt, ContextVision, CurveBeam AI, Diagnos and more.
INIFY Laboratories Overview
About INIFY Laboratories
INIFY Laboratories AB provides cancer diagnostics through ultra-modern laboratory services within pathology. It uses a fully digital, standardized, and AI-supported workflow to optimize quality and response times, initially within the prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization.
Founded
2021
HQ
Employees
26
Website
Financials (FY)
EV
$21M
INIFY Laboratories Financials
INIFY Laboratories reported last fiscal year revenue of $1M and negative EBITDA of ($5M).
In the same fiscal year, INIFY Laboratories generated $1M in gross profit, ($5M) in EBITDA losses, and had net loss of ($6M).
INIFY Laboratories P&L
In the most recent fiscal year, INIFY Laboratories reported revenue of $1M and EBITDA of ($5M).
INIFY Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 86% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (357%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (404%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($6M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (393%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
INIFY Laboratories Stock Performance
INIFY Laboratories has current market cap of $33M, and enterprise value of $21M.
Market Cap Evolution
INIFY Laboratories' stock price is $0.41.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $21M | $33M | (0.5%) | XXX | XXX | XXX | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialINIFY Laboratories Valuation Multiples
INIFY Laboratories trades at 14.7x EV/Revenue multiple, and (4.1x) EV/EBITDA.
INIFY Laboratories Financial Valuation Multiples
As of March 7, 2026, INIFY Laboratories has market cap of $33M and EV of $21M.
Equity research analysts estimate INIFY Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
INIFY Laboratories has a P/E ratio of (5.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $33M | XXX | $33M | XXX | XXX | XXX |
| EV (current) | $21M | XXX | $21M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 14.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (3.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 17.2x | XXX | XXX | XXX |
| P/E | — | XXX | (5.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified INIFY Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
INIFY Laboratories Margins & Growth Rates
INIFY Laboratories' revenue in the last fiscal year grew by 1001%.
INIFY Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 1001% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (357%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (4%) | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 489% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
INIFY Laboratories Public Comps
See public comps and valuation multiples for other Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Novacyt | XXX | XXX | XXX | XXX | XXX | XXX |
| ContextVision | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Diagnos | XXX | XXX | XXX | XXX | XXX | XXX |
| NanoRepro | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
INIFY Laboratories M&A Activity
INIFY Laboratories acquired XXX companies to date.
Last acquisition by INIFY Laboratories was on XXXXXXXX, XXXXX. INIFY Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by INIFY Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialINIFY Laboratories Investment Activity
INIFY Laboratories invested in XXX companies to date.
INIFY Laboratories made its latest investment on XXXXXXXX, XXXXX. INIFY Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by INIFY Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout INIFY Laboratories
| When was INIFY Laboratories founded? | INIFY Laboratories was founded in 2021. |
| Where is INIFY Laboratories headquartered? | INIFY Laboratories is headquartered in Sweden. |
| How many employees does INIFY Laboratories have? | As of today, INIFY Laboratories has over 26 employees. |
| Is INIFY Laboratories publicly listed? | Yes, INIFY Laboratories is a public company listed on Oslo Børs. |
| What is the stock symbol of INIFY Laboratories? | INIFY Laboratories trades under INIFY ticker. |
| When did INIFY Laboratories go public? | INIFY Laboratories went public in 2022. |
| Who are competitors of INIFY Laboratories? | INIFY Laboratories main competitors are Novacyt, ContextVision, CurveBeam AI, Diagnos. |
| What is the current market cap of INIFY Laboratories? | INIFY Laboratories' current market cap is $33M. |
| What is the current revenue of INIFY Laboratories? | INIFY Laboratories' last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of INIFY Laboratories? | Current revenue multiple of INIFY Laboratories is 14.7x. |
| Is INIFY Laboratories profitable? | No, INIFY Laboratories is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.